Popular Trials
Guselkumab for Psoriatic Arthritis
Recruiting2 awardsPhase 4
Phoenix, Arizona
This trial is testing guselkumab, a medication that reduces inflammation, in patients with psoriatic arthritis affecting the spine. It works by blocking a protein called IL-23 to help reduce symptoms and inflammation. Guselkumab is the first IL-23 specific inhibitor approved for the treatment of moderate-to-severe psoriasis.
Deucravacitinib for Psoriatic Arthritis
Recruiting1 awardPhase 3
Fountain Valley, California
This trial is testing a new medication called deucravacitinib to see if it can help people with psoriatic arthritis who haven't tried advanced treatments. The medication works by reducing joint swelling and pain by blocking inflammation. Deucravacitinib is a new oral drug that has shown good results in previous studies for psoriasis.
Deucravacitinib for Psoriatic Arthritis
Recruiting1 awardPhase 3
New York, New York
This trial is testing a new medication called deucravacitinib to help people with active Psoriatic Arthritis. It aims to reduce joint pain and swelling by blocking harmful signals in the body. The study includes people who haven't tried biologic treatments or need an alternative to TNFα inhibitors. Deucravacitinib is an emerging treatment option for Psoriatic Arthritis, showing promise in recent studies.
Monoclonal Antibodies
Tildrakizumab for Psoriatic Arthritis
Recruiting1 awardPhase 3
Covina, California
This trial is testing tildrakizumab, a medication that reduces inflammation, in patients with active Psoriatic Arthritis who haven't tried certain other treatments. It works by blocking a protein to help manage symptoms. Tildrakizumab is approved for treating moderate to severe plaque psoriasis.
Popular Filters
Trials for Juvenile Idiopathic Arthritis Patients
Behavioural Intervention
Shared Decision Making for Juvenile Arthritis
Recruiting1 award
Vancouver, British Columbia
This trial is testing whether a discussion between physicians and families, using a computer-generated personalized outcome report, will improve the tailoring of treatment to the child and control of their disease.
Monoclonal Antibodies
Sarilumab for Juvenile Idiopathic Arthritis
Recruiting1 awardPhase 2
Calgary, Alberta
This trial is testing sarilumab, a medication that reduces inflammation, in children and teenagers with a specific type of arthritis called sJIA. The medication works by blocking a protein that causes inflammation.
Anti-metabolites
Reduced-Intensity Stem Cell Transplant for Non-Malignant Disorders
Recruiting1 awardPhase 2
Pittsburgh, Pennsylvania
This trial is testing whether a reduced-intensity conditioning regimen followed by umbilical cord blood transplant, double cord blood transplant, matched unrelated donor bone marrow transplant, or peripheral blood stem cell transplant is effective in treating patients with non-malignant disorders.
Behavioral Intervention
Mindfulness Program for Children with Juvenile Arthritis
Recruiting1 award1 criteria
Hamilton, Ontario
"This trial will assess the effectiveness of a program called Making Mindfulness Matter (M3) for children with Juvenile arthritis and their parents. The program is an 8-week online intervention that combines mindfulness
Behavioural Intervention
Virtual Self-Management Program for Juvenile Arthritis
Recruiting1 award
Calgary, Alberta
This trial aims to test a virtual self-management program for adolescents with JIA across different provinces. Participants will be divided into two groups - one group will participate in the program while the other group will receive
Trials With No Placebo
Procedure
Ulcer Healing Analysis for Inflammatory Bowel Disease
Recruiting1 award7 criteria
Lexington, Kentucky
This trial involves taking small pieces of tissue from the colon to study how ulcers heal. It includes patients with inflammatory bowel disease, arthritis, and healthy individuals to compare healing processes. Researchers will examine how genes work and how cells produce energy to understand healing.
Monoclonal Antibodies
Guselkumab vs Golimumab for Psoriatic Arthritis
Recruiting2 awardsPhase 3
Philadelphia, Pennsylvania
This trial will compare two medications, guselkumab and golimumab, in patients with psoriatic arthritis who did not respond well to their initial treatment. The goal is to see if switching to guselkumab is more effective than trying another similar medication. Guselkumab is used for treating moderate-to-severe plaque psoriasis in adults and has shown additional benefits in patients who did not respond well to other treatments.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.